Advertisement

Biogen Idec (NASDAQ: BIIB) is awaiting approval from the U.S. Food and Drug Administration for its first oral multiple sclerosis therapy, and has released new Phase 3 data that shows positive efficacy and safety for the drug candidate. The FDA is scheduled to make a decision on or before Dec. 28.

Advertisement
Advertisement